• Change country/language

    Looks like you’re in {} — you’re on the {} site.

    Cancel

    Country and language selected

    You are being redirected to the {} site. Products and services availability vary by country. Do you wish to continue?

    Continue
    Cancel
Press Releases

Kalbe and GE HealthCare Launch Indonesia’s First CT-Scanner Production Facility

June 02, 2025

Bogor, Indonesia 

  • Kalbe, through its subsidiary Forsta, and GE HealthCare have launched Indonesia’s first CT scanner production facility
  • The facility will improve access to advanced diagnostic technology, accelerate delivery to healthcare providers in Indonesia
  • The initiative supports national healthcare resilience, creates skilled jobs, fosters innovation and aligns with government priorities for local medical device manufacturing

In a significant move to strengthen Indonesia’s healthcare infrastructure, PT Kalbe Farma Tbk (Kalbe) and GE HealthCare have officially inaugurated the country’s first production facility dedicated to manufacturing technologically advanced CT (Computed Tomography) scanners. Located at PT Forsta Kalmedic Global (Forsta) in Bogor.  The facility is a milestone in localizing advanced medical device production and enhancing diagnostic capabilities across the nation.

The launch ceremony was attended by Indonesia’s Director General Pharmaceutical and Medical Device, Ministry of Health, Lucia Rizka Andalusia and Deputy for Licensing and Inspection from the Nuclear Energy Regulatory Agency, Zainal Arifin, together with Elie Chaillot, President & CEO of GE HealthCare International and Irawati Setiady, President Director of Kalbe. 

This pioneering production facility is the result of a strategic collaboration between Kalbe Farma’s subsidiary Forsta and GE HealthCare.  It marks a major advancement in the country’s ambition to build a resilient, self-reliant healthcare system—by accelerating access to medical imaging technology and developing local manufacturing expertise.

“This facility will help us respond faster to local needs while maintaining the highest international standards of quality and safety,” said Elie Chaillot. “This production facility improves access to critical advanced diagnostic technology, creates high value jobs and supports the development of Indonesia’s health technology workforce.”

With a population of over 280 million spread across thousands of islands, Indonesia faces unique challenges in healthcare access.  By establishing local production, Kalbe and GE HealthCare aim to reduce reliance on imports, cut delivery times, and make life-saving diagnostic tools more accessible to hospitals and clinics nationwide.

“The strategic partnership between Kalbe and GE HealthCare to supply CT scan machines locally exemplifies Kalbe’s commitment to government efforts focused on supporting national health resilience and local health industry self-sufficiency. We hope that by producing the CT Scan machines domestically will also enhance healthcare services and improving the quality of life for the Indonesian population,” stated Irawati.

CT scan is a widely used health diagnostic tool known for its detailed capabilities in identifying various diseases. “The establishment of CT scan machines local production is among the top ten health devices prioritized for local production. Therefore, establishing a domestic CT scan production facility is crucial for enhancing access to broader healthcare services. Forsta is proud to play a role in strengthening Indonesia’s ability to meet its own healthcare needs,” stated Yvone Astri Della Sijabat, Director of Forsta.

The new production facility is also expected to create high-value employment opportunities, supporting the growth of Indonesia’s health technology workforce and enabling knowledge transfer in advanced medical manufacturing.

CT scanners are among the ten medical devices prioritized by the Indonesian government for domestic production. This investment supports that policy while laying the foundation for future innovation and greater healthcare independence.

 

Copy article text Link copied to clipboard

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

 

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

 

Follow us on LinkedIn, FacebookInstagram, or visit our website for our latest news and perspectives

About PT Kalbe Farma Tbk

PT Kalbe Farma Tbk (Kalbe) was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle a portfolio of dependable and various brands: the prescription pharmaceutical division, the health products division that handles over-the-counter drugs, multivitamins, and ready-to-serve supplemental drinks, the nutritions division, and the distribution & logistics division.

Kalbe has also developed B2B-based digital services ecosystems for the society: EMOS and MOSTRANS. EMOS is an order management application system that helps distribution channels perform their stock or supply chain management actions. MOSTRANS is a B2B transportation solution provider for the easy management and the efficiency of transportation.

Kalbe now has more than 49 subsidiaries and 14 international-standard production facilities, supported by around 16,000 employees in 71 branches throughout Indonesia. Kalbe’s shares have been listed in Indonesia Stock Exchange/Bursa Efek Indonesia (IDX:KLBF) since 1991. For more information, please visithttps://www.kalbe.co.id/

Forsta at a Glance

  • PT Forsta Kalmedic Global (www.forsta.co.id) is a subsidiary that was established in 2019 to support the government in national resilience in the medical equipment industry. Forsta has the capability to produce various products that can meet regulation requirements of the international market.
  • Forsta has obtained production certificates, a CPAKB (Cara Pembuatan Alat Kesehatan yang Baik/Good Medical Device Manufacturing Practice) certificate, an ISO 13485 certificate, a halal certificate, a TKDN (Tingkat Komponen Dalam Negeri/Domestic Component Level) certificate, and licensing from the BAPETEN.
  • The production of Elva, a commercial surgical thread, has been run since December 2021 with its first product, Elvalene, a synthetic polypropylene thread that cannot be absorbed. In 2022, Elvalene was listed in e-catalogues and was tested in several educational hospitals in the island of Java. Elvalene has also been certified halal and has obtained a TKDN certificate with more than 40% of domestic component level.
  • In February & March 2023, Forsta launched more products to make their portfolio more complete such as synthetic surgical threads that are absorbable: Elvacryl, Elvadio, Elvamono, Elvarapid; as well as natural surgical threads that are absorbable: Elvaplain, Elvachromic. This portfolio could meet the main needs of surgical threads in the market.
  • Forsta has signed an MoU with two Italian technology companies, Tecnoideal and BMI, as their technology partners to build manufacturing competence of various medical equipment products with Indonesia’s technology content.

For more information please visit https://www.forsta.co.id/MOS

 

JB33618XX June 2025